152 related articles for article (PubMed ID: 2645036)
1. Comparison of the antitumor activity of cisplatin, carboplatin, and iproplatin against established human testicular cancer cell lines in vivo and in vitro.
Harstrick A; Casper J; Guba R; Wilke H; Poliwoda H; Schmoll HJ
Cancer; 1989 Mar; 63(6):1079-83. PubMed ID: 2645036
[TBL] [Abstract][Full Text] [Related]
2. Comparative antitumour activity of cisplatin and two new cisplatin-analogues JM8 and JM9 in human testicular carcinoma xenografts.
Harstrick A; Casper J; Schmoll HJ
Int J Androl; 1987 Feb; 10(1):139-45. PubMed ID: 3034790
[TBL] [Abstract][Full Text] [Related]
3. Resistance and cross-resistance of the IgM immunocytoma in the LOU/M Wsl rat for cisplatin, carboplatin, and iproplatin.
Steerenberg PA; Vendrik CP; de Jong WH; de Groot G; Fichtinger-Schepman AM; Scheefhals AP; Schornagel JH
Cancer Chemother Pharmacol; 1988; 22(1):51-7. PubMed ID: 3293840
[TBL] [Abstract][Full Text] [Related]
4. Quantitative ultrastructural effects of cisplatin (Platinol), carboplatin (JM8), and iproplatin (JM9) on neurons of freshwater snail Lymnaea stagnalis.
Müller LJ; Moorer-van Delft CM; Roubos EW; Vermorken JB; Boer HH
Cancer Res; 1992 Feb; 52(4):963-73. PubMed ID: 1737358
[TBL] [Abstract][Full Text] [Related]
5. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines.
Harstrick A; Bokemeyer C; Scharnofkse M; Hapke G; Reile D; Schmoll HJ
Cancer Chemother Pharmacol; 1993; 33(1):43-7. PubMed ID: 8269588
[TBL] [Abstract][Full Text] [Related]
6. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
7. Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery.
Kelland LR; Jones M; Abel G; Valenti M; Gwynne J; Harrap KR
Cancer Chemother Pharmacol; 1992; 30(1):43-50. PubMed ID: 1586979
[TBL] [Abstract][Full Text] [Related]
8. The relative effectiveness of analogues of cisplatin in the experimental chemotherapy of human non-small-cell lung cancer and neuroblastoma grown as multicellular spheroids.
Russell J; Adam J; Wheldon TE; Kaye SB
Cancer Chemother Pharmacol; 1989; 23(2):111-4. PubMed ID: 2535968
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of cisplatin analogs against malignant ovarian tumor xenografts into nude mice.
Hamaguchi K; Miyahara K; Nishimura H; Tashiro M; Kishi N; Matsumura T; Yakushiji M; Kato T
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Nov; 40(11):1755-9. PubMed ID: 3069943
[TBL] [Abstract][Full Text] [Related]
10. [Antitumor effect of JM-8 (a cisplatin analogue) on testicular cancer cells in vitro and in vivo].
Hashimura T; Okada K; Yoshida O
Gan To Kagaku Ryoho; 1985 May; 12(5):1137-42. PubMed ID: 3888118
[TBL] [Abstract][Full Text] [Related]
11. Advantages in combination chemotherapy using cisplatin and its analogues for human testicular tumor xenografts.
Hida S; Okada K; Yoshida O
Jpn J Cancer Res; 1990 Apr; 81(4):425-30. PubMed ID: 2114395
[TBL] [Abstract][Full Text] [Related]
12. Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.
Sasaki Y; Shinkai T; Eguchi K; Tamura T; Ohe Y; Ohmori T; Saijo N
Cancer Chemother Pharmacol; 1991; 27(4):263-70. PubMed ID: 1847845
[TBL] [Abstract][Full Text] [Related]
13. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
14. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
Twentyman PR; Wright KA; Mistry P; Kelland LR; Murrer BA
Cancer Res; 1992 Oct; 52(20):5674-80. PubMed ID: 1327513
[TBL] [Abstract][Full Text] [Related]
16. Cell survival in four ovarian carcinoma xenografts following in vitro exposure to melphalan, cisplatin and cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA,JM8).
Jones AC; Wilson PA; Steel GG
Cancer Chemother Pharmacol; 1984; 13(2):109-13. PubMed ID: 6380788
[TBL] [Abstract][Full Text] [Related]
17. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
Sun X; Lou LG; Sui DH; Wu XH
Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of platinum analogs against human lung cancer cell lines and tumor specimens.
Yonei T; Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Moritaka T; Shibayama T; Tabata M; Segawa Y; Takigawa N
Acta Med Okayama; 1993 Aug; 47(4):233-41. PubMed ID: 8213217
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma.
Cantwell BM; Franks CR; Harris AL
Cancer Chemother Pharmacol; 1986; 18(3):286-8. PubMed ID: 3542271
[TBL] [Abstract][Full Text] [Related]
20. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
Goddard PM; Orr RM; Valenti MR; Barnard CF; Murrer BA; Kelland LR; Harrap KR
Anticancer Res; 1996; 16(1):33-8. PubMed ID: 8615631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]